X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The commercial agreement includes potential expansion of Kedrion's distribution of Kedrab, a Human Rabies Immune Globulin, in additional territories beyond the US. In addition, the two companies will collaborate to expand distribution of Kedrion products by Kamada in Israel.
Lead Product(s): Rabies Immune Globulin (Human)
Therapeutic Area: Infections and Infectious Diseases Product Name: Kedrab
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Kedrion
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 07, 2023
Details:
The agreement aims for the distribution of Kedrab (Rabies Immune Globulin [Human]), which is indicated for passive, transient post-exposure prophylaxis of rabies infection to persons of all ages when given immediately after contact with a rabid, in the U.S.
Lead Product(s): Human Rabies Immune Globulin
Therapeutic Area: Immunology Product Name: Kedrab
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Kedrion
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 12, 2023
Details:
Glassia is an Alpha1 -Proteinase Inhibitor (Human), indicated for chronic augmentation and maintenance therapy in individuals with clinically evident emphysema due to severe hereditary deficiency of Alpha1, also known as alpha1-antitrypsin (AAT) deficiency.
Lead Product(s): Human Alpha1-Proteinase Inhibitor
Therapeutic Area: Genetic Disease Product Name: Glassia
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
Cytogam (Human cytomegalovirus) Immuno Globulin Intravenous is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas and heart.
Lead Product(s): Cytomegalovirus Human Immune Globulin
Therapeutic Area: Infections and Infectious Diseases Product Name: Cytogam
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2023
Details:
Cytogam (Human cytomegalovirus) Immuno Globulin Intravenous is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas and heart.
Lead Product(s): Human Cytomegalovirus Immune Globulin
Therapeutic Area: Infections and Infectious Diseases Product Name: Cytogam
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
Under the terms of the agreement, Kamada is responsible for the commercialization of Zeqmelit™ (dexamethasone) in Israel and has the exclusive right to marketing, sales, and distribution of the drug in this market.
Lead Product(s): Dexamethasone
Therapeutic Area: Immunology Product Name: Zeqmelit
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: AcuCort
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 23, 2022
Details:
The Company’s commercial products portfolio includes its developed and FDA approved products GLASSIA® and KEDRAB® as well as its recently acquired FDA approved plasma derived hyperimmune products CYTOGAM®, HEPAGAM B®, VARIZIG® and WINRHO®SDF.
Lead Product(s): Human Alpha1-proteinase
Therapeutic Area: Genetic Disease Product Name: Glassia
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
VARIZIG (Varicella Zoster Immune Globulin), one of four acquired FDA-approved commercial products by Kamada, contains antibodies specific for the Varicella zoster virus, and is indicated for post-exposure prophylaxis of varicella (chickenpox) in high-risk patient groups.
Lead Product(s): Varicella Zoster Immune Globulin (Human)
Therapeutic Area: Infections and Infectious Diseases Product Name: Varizig
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $11.4 million Upfront Cash: Undisclosed
Deal Type: Agreement July 06, 2022
Details:
GLASSIA, is an Alpha1 -Proteinase Inhibitor (Human), indicated for chronic augmentation and maintenance therapy in individuals with clinically evident emphysema due to severe hereditary deficiency of Alpha1 -PI, also known as alpha1 -antitrypsin deficiency.
Lead Product(s): Alpha1-Proteinase Inhibitor
Therapeutic Area: Genetic Disease Product Name: Glassia
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
Under the terms of the agreement, Kamada Inc., will be responsible for the commercialization of the CYTOGAM®, WINRHO®, HEPAGAM B®, and VARIZIG® in the U.S., including direct sales to wholesalers and local distributers.
Lead Product(s): Cytomegalovirus Immune Globulin [Human],Ganciclovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Cytogam
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Saol therapeutics
Deal Size: $145.0 million Upfront Cash: $95.0 million
Deal Type: Acquisition November 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
